Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06983743 · ClinicalTrials.gov registry record · Phase 1
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study of Metastatic Solid Tumors, sponsored by Erasca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 5
- Study locations
NCT06983743 is a Phase 1 study of Metastatic Solid Tumors that is actively recruiting participants, run by Erasca. The registered enrollment target is 200 participants, roughly in line with the 196-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target. The trial reports 5 study locations across 4 states.
The verdict
NCT06983743, a Phase 1 study of Metastatic Solid Tumors, is actively recruiting participants, sponsored by Erasca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Conditions Studied
Interventions
- DRUG ERAS-0015
- DRUG ERAS-0015 in combination
Study Locations (5)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- University of Texas at Tyler - Tyler
Florida
- Florida Cancer Specalists - Sarasota
New York
- Memorial Sloan Kettering Cancer Center - New York
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06983743
The ClinicalTrials.gov registry entry for NCT06983743 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 196-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target. The listed sponsor is Erasca, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which ERAS-0015 is the first listed.
NCT06983743 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06983743 about?
NCT06983743 is a clinical study titled "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors". The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
What is the current status of trial NCT06983743?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2025-06-05. Estimated completion is 2028-12-01.
What conditions does trial NCT06983743 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors.
What interventions are being tested in trial NCT06983743?
The interventions under investigation include: ERAS-0015 (DRUG), ERAS-0015 in combination (DRUG).
Who is sponsoring clinical trial NCT06983743?
This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06983743 being conducted?
This trial has 5 study locations across Florida, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SLV-324 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.